PCRX Pacira Biosciences Inc.

Pacira Pharmaceuticals to Present at Healthcare Conferences in November

Pacira Pharmaceuticals to Present at Healthcare Conferences in November

PARSIPPANY, N.J., Nov. 08, 2018 (GLOBE NEWSWIRE) -- (NASDAQ: PCRX) today announced that members of its management team are scheduled to present at the following healthcare conferences:

  • Jefferies 2018 Healthcare Conference in London, on Wednesday, November 14, 2018 at 2:40 PM GMT (9:40 AM ET)
  • Piper Jaffray 30th Annual Healthcare Conference in New York, on Tuesday, November 27, 2018 at 12:30 PM ET

A live audio webcast of the Pacira presentations can be accessed by visiting the “Investors & Media” section of the company’s website at . A replay of the webcasts will be archived on the Pacira website for two weeks following the presentation dates.

About Pacira                                                                           

Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) is a specialty pharmaceutical company dedicated to advancing and improving postsurgical outcomes for acute care practitioners and their patients. The company’s flagship product, EXPAREL® (bupivacaine liposome injectable suspension) was commercially launched in the United States in April 2012. EXPAREL utilizes DepoFoam®, a unique and proprietary product delivery technology that encapsulates drugs without altering their molecular structure, and releases them over a desired period of time. To learn more about Pacira, including the corporate mission to reduce overreliance on opioids, visit .

Company Contact:
Pacira Pharmaceuticals, Inc.
Christian Pedetti
(973) 254-4387
EN
08/11/2018

Underlying

PCRXPacira Biosciences Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Pacira Biosciences Inc.

 PRESS RELEASE
Free
PCRX Pacira Bioscien...

Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule...

Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BRISBANE, Calif., March 06, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of patients, today announced the granting of inducement awards on March 3, 2026 to three new employees under Pacira’s Amended and Restated 2014 Inducement Plan (the “Inducement Plan”) as a material inducement to each employee’s entry into employment with the company. In accordance with Nasdaq Listing Rule 5635(c)(4), ...

16h / 45m 1 EN
 PRESS RELEASE
Free
PCRX Pacira Bioscien...

Pacira BioSciences to Participate in Fireside Chat at the Barclays 28t...

Pacira BioSciences to Participate in Fireside Chat at the Barclays 28th Annual Global Healthcare Conference BRISBANE, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that it will participate in an analyst-led fireside chat at the Barclays 28th Annual Global Healthcare Conference at 2:30 PM ET on Wednesday, March 11, 2026 in Miami. Live audio of the event can be accessed by visiting the “Events” page of the company’s ...

March 4, 2026 1 EN
 PRESS RELEASE
Free
PCRX Pacira Bioscien...

Pacira BioSciences Presents Two Real-World Studies from Its Innovation...

Pacira BioSciences Presents Two Real-World Studies from Its Innovations in Genicular Outcomes Registry (IGOR) -- Studies highlight the clinical effectiveness of EXPAREL for total knee arthroplasty and long-term pain management with ioveraº for patients with osteoarthritis (OA) of the knee -- -- Data presented at the American Academy of Orthopedic Surgeons 2026 Annual Meeting -- BRISBANE, Calif., March 02, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of p...

March 2, 2026 1 EN
 PRESS RELEASE
Free
PCRX Pacira Bioscien...

Pacira BioSciences Reports Fourth Quarter and Full-Year 2025 Financial...

Pacira BioSciences Reports Fourth Quarter and Full-Year 2025 Financial Results — Record-high EXPAREL sales driven by volume growth of 7 percent, marking strongest fourth quarter performance in three years — — Conference call today at 4:30 p.m. ET — BRISBANE, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today reported financial results for the fourth quarter and full-year of 2025. “2025 was a year of disciplined execution for P...

February 26, 2026 1 EN
 PRESS RELEASE
Free
PCRX Pacira Bioscien...

Pacira to Report 2025 Financial Results on Thursday February 26, 2026

Pacira to Report 2025 Financial Results on Thursday February 26, 2026 BRISBANE, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that it will report its fourth quarter and year ended December 31, 2025 financial results after the close of the U.S. markets on Thursday February 26, 2026. Following the release, the company will host a live conference call and webcast at 4:30 p.m. ET. For listeners who wish to participate ...

February 12, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch